%0 Journal Article
%T Production, quality control and biodistribution studies of 166Ho-EDTMP therapeutic radiopharmaceutical
%A Reza Bagheri
%A Ali Bahrami-Samani
%A Simindokht Shirvani-Arani
%A Mohammad Ghannadi-Maragheh
%J Iranian Journal of Nuclear Medicine
%D 2010
%I 
%X Introduction: Bone metastases are a frequent complication of cancer that frequently causes intense pain. Pain palliation of these cancers is one of important goals in nuclear medicine. Therapeutic radiopharmaceuticals are widely used to palliate pain of bone metastases. Among some radiopharmaceuticals which are useful for radiotherapy, holmium-166 ethylenediamine-tetramethylenephosphonicacid (166Ho-EDTMP) is of particular interest for larger tumors. 166Ho is a beta and gamma emitter with a high beta energy and appropriate half- life and gamma ray (81 keV) for imaging studies. Methods: 166Ho was prepared by neutron activation of natural 165Ho sample (purity > 99/8%) and complex was obtained in room temperature by adding EDTMP ligand. In this research radiochemical purity was checked by paper chromatography and radionuclidic purity by recording the gamma ray spectra using a gamma spectrometer with an HPGe detector. The biodistribution studies of radiopharmaceutical, then was performed using wild type rats. In addition, the image was taken at 4 hours after administration of the radiopharmaceutical by a dual-head SPECT system. Results: 166Ho-EDTMP was prepared in excellent purity (above 99% in 30 minutes) and with high in-vitro stability. The major deposition of radiopharmaceutical (>70%) was found in bone, while radiopharmaceutical did not practically accumulate in other organs. Conclusion: 166Ho-EDTMP is a promising agent for bone pain palliation therapy in skeletal metastases in human with low undesired dose to other organs in rodents
%K Bone metastases
%K 166Ho-EDTMP
%K Radiopharmaceutical
%K Biodistribution
%U http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/16978.pdf&manuscript_id=16978